Scleromyxedema: A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG)

Medicine

Volumn 87, Issue 1, 2008, Pages 10-20

  Blum, Marissa ^a,b   Wigley, Fredrick M ^a   Hummers, Laura K ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BORTEZOMIB; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUOCINONIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERFERON; ISOTRETINOIN; METHOTREXATE; METHOXSALEN; METHYLPREDNISOLONE; METRONIDAZOLE; MUCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISONE; STEROID; THALIDOMIDE;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG INFUSION; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPERTENSION; KIDNEY FAILURE; LEUKOPENIA; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYALGIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; PUVA; RASH; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SCLEROMYXEDEMA; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOM; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; WEAKNESS;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; LUNG DISEASES; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; RETROSPECTIVE STUDIES; SCLEROMYXEDEMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 38349190093     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e3181630835     Document Type: Article

References (38)

1. Berger JR, Dobbs MR, Terhune MH, Maragos WF. The neurologic complications of scleromyxedema. Medicine (Baltimore). 2001;80:313-319.
2. Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol. 2004;140:277-280.
3. Craig NM, Putterman AM, Roenigk RK, Wang TD, Roenigk HH. Multiple periorbital cutaneous myxomas progressing to scleromyxedema. J Am Acad Dermatol. 1996;34:928-930.
4. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33:37-43.
5. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, Duvic M. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006;107:463-466.
6. Dubreuilh W. Fibromes miliaires folliculaires: sclerodemie consecutive. Ann Dermatol Syph. 1906;37:569-572.
7. Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol. 2001;137:1071-1072.
8. Feldman P, Shapiro L, Pick AI, Slatkin MH. Scleromyxedema. A dramatic response to melphalan. Arch Dermatol. 1969;99:51-56.
9. Ferrarini M, Helfrich DJ, Walker ER, Medsger TA Jr, Whiteside TL. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol. 1989;16:837-841.
10. Gabriel SE, Perry HO, Oleson GB, Bowles CA. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore). 1988;67:58-65.
11. Gottron HA. [Scleromyxedema; a strange manifestation of myxothesaurodermy.]. Arch Klin Exp Dermatol. 1954;199:71-91.
12. Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science. 1978;199:545-547.
13. Harris RB, Perry HO, Kyle RA, Winkelmann RK. Treatment of scleromyxedema with melphalan. Arch Dermatol. 1979;115:295-299.
14. Helm F, Helm TN. Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema. Cutis. 1987;39:219-223.
15. Horn KB, Horn MA, Swan J, Singhal S, Guitart J. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema J Am Acad Dermatol. 2004;51(2 Suppl):S120-123.
16. Illa I, de la Torre C, Rojas-Garcia R, Altes A, Blesa R, Sierra J, Gallardo E. Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study. Blood. 2006;108:773-774.
17. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228-1231.
18. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670-673.
19. Kantor GR, Bergfeld WF, Katzin WE, Reynolds OD, Biscardi AP, Lobur DM, Box TA, Schreiber MJ Jr, Ratliff NB. Scleromyxedema associated with scleroderma renal disease and acute psychosis. J Am Acad Dermatol. 1986;14:879-888.
20. Karim A, Lawlor F, Black MM. Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol. 2004;29:317-318.
21. Keong CH, Asaka Y, Fukuro S, Miyamoto C, Katsumata M, Iino Y, Komiya T. Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol. 1990;22:842-844.
22. Kulczycki A, Nelson M, Eisen A, Heffernan M. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol. 2003;149:1276-1281.
23. Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler. 2004;10:85-86.
24. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, Kumar S, Litzow MR, Schroeter AL. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol. 2005;141:1277-1282.
25. Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M, Rustin MH. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol. 2000;43:403-408.
26. Montgomery H, Underwood L. Lichen myxedematosus; differentiation from cutaneous myxedema or mucoid states. J Invest Dermatol. 1953;20:213-236.
27. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol. 2003;42:31-35.
28. Reitmann K. Uber eine eigenartige, der Sklerodermie nahestehende Affektion. Arch Dermatol Syph. 1908;92:417-424.
29. Righi A, Schiavon F, Jablonska S, Doria A, Blasczyk M, Rondinone R, Todesco S, Matucci Cerinic M. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis. 2002;61:59-61.
30. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44:273-281.
31. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
32. Sansbury JC, Cocuroccia B, Jorizzo JL, Gubinelli E, Gisondi P, Girolomoni G. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol. 2004;51:126-131.
33. Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci. 2005;1051:743-778.
34. Shergill B, Orteu CH, McBride SR, Rustin MH. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin. Br J Dermatol. 2005;153:650-652.
35. Westheim AI, Lookingbill DP. Plasmapheresis in a patient with scleromyxedema. Arch Dermatol. 1987;123:786-789.
36. Wetter DA, Davis MD, Yiannias JA, Gibson LE, Dahl MV, el-Azhary RA, Bruce AJ, Lookingbill DP, Ahmed I, Schroeter AL, Pittelkow MR. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc. 2005;80:41-47.
37. Wojas-Pelc A, Blaszczyk M, Glinska M, Jablonska S. Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins. J Eur Acad Dermatol Venereol. 2005;19:462-465.
38. Yaron M, Yaron I, Yust I, Brenner S. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol. 1985;12:171-175.